Filing Flows › Comparisons › VIR vs RVMD
Vir Biotechnology vs Revolution Medicines: VIR and RVMD compared
Vir Biotechnology is the larger company: $239M of revenue in its latest quarter (Q2 2026) against $198M for Revolution Medicines (Q3 2026). Vir Biotechnology is more profitable, with an operating margin of 30.7% against -188.9%.
Where the money goes: VIR and RVMD
Vir Biotechnology (VIR) · Q2 2026
Vir Biotechnology, Q2 2026: revenue $239M (197× year over year), operating margin 30.7%, net earnings $80.1M, operating cash flow $123M. The chart follows the revenue to costs, profit and cash.
Revolution Medicines (RVMD) · Q3 2026
Revolution Medicines, Q3 2026: revenue $198M, operating margin -188.9%, net loss $407M, operating cash flow −$416M. The chart follows the revenue to costs, profit and cash.
| Vir Biotechnology (VIR) | Revolution Medicines (RVMD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $239M | $198M |
| Revenue growth, Y/Y | 197× | — |
| Operating margin | 30.7% | -188.9% |
| Net earnings | $80.1M | −$407M |
| Net margin | 33.5% | -206.2% |
| Operating cash flow | $123M | −$416M |
| Free cash flow | $123M | — |
Where the revenue comes from
Vir Biotechnology
- License and collaboration revenue: $239M (100%)
- Grant revenue: $11K (0%)
Questions
Which is bigger, Vir Biotechnology or Revolution Medicines?
Vir Biotechnology is the larger company: $239M of revenue in its latest quarter (Q2 2026) against $198M for Revolution Medicines (Q3 2026).
Is Vir Biotechnology or Revolution Medicines growing faster?
Vir Biotechnology is more profitable, with an operating margin of 30.7% against -188.9%.
More: Vir Biotechnology earnings · how Vir Biotechnology makes money · Revolution Medicines earnings · how Revolution Medicines makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.